Sami-Sabinsa Group hosted a ground-breaking ceremony, on January 20, 2020, for a new Active Pharmaceutical Ingredients
(API) manufacturing unit at Pharma SEZ Industrial Area, Hassan, Karnataka. The latest facility, with a planned investment of $30 Million USD, is part of the group’s strategy to expand existing ingredient growth, and focus on innovative new products. This will be the company’s eighth manufacturing facility.
Shri. Prajwal Gowda, Member of Parliament (MP), Hassan, and Shri. Preetham J. Gowda, Member of the Legislative Assembly (MLA), graced the ceremony, along with the senior management team of Sami-Sabinsa Group and employees of Sami Labs.
Commenting on the occasion, Dr. Muhammed Majeed, Founder and Chairman, Sami-Sabinsa Group, said, “We have been doing business in India for nearly three decades now, and our business has grown rapidly over the years. The upcoming production facility at Hassan will not only empower us to cater to the entire global market with patented and off-patent API products but will also play a vital role in boosting the export sales of the Sami-Sabinsa Group and help in doubling the company revenue.”
The first phase covering 430,556 square feet of this world-class API manufacturing unit will have a production capacity of more than 300 tons per annum. The high quality, environmentally conscious, Zero Liquid Discharge (ZLD) facility will combine user comfort, energy efficiency, responsible water management, and biodiversity development. The facility, which will be 100% cGMP and compliant with regulatory requirements, is scheduled for commissioning by 2021 and is expected to generate employment for approximately 400 people in and around Hassan.
About Sabinsa
Sabinsa, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, probiotics, minerals, and specialty fine chemicals. The company markets over 100 standardized botanical extracts and employs more than 1000 people worldwide in 12 manufacturing, R&D, sales, and distribution facilities. Process development and product innovation form the focus of the ongoing R&D efforts in the company’s research facilities, located in India and the U.S. products, many of which are both Kosher and Halal, are extensively researched, patented, and supported by hundreds of published clinical studies. Sabinsa’s botanical cultivation program totals nearly 40,000 acres to ensure sustainable, fair trade materials are used in these ingredients.
